MAGEA3 and non-small cell lung carcinoma: To further verify the antigenicity of the candidate MAGE-A3 epitopes, a cohort including 25 HLA-A2+ NSCLC donors was recruited (Table S1) for epitope-specific CD8+ T cells screening and characterization (Figure 3A).